Modality
mRNA
MOA
KRASG12Di
Target
PRMT5
Pathway
JAK/STAT
LNAS
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Apr 2031
Phase 2Current
NCT03182876
1,394 pts·LN
2018-12→TBD·Terminated
NCT06105090
1,777 pts·AS
2019-11→2031-04·Terminated
3,171 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-285.1y awayPh2 Data· AS
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Termina…
P2
Termina…
Catalysts
Ph2 Data
2031-04-28 · 5.1y away
AS
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03182876 | Phase 2 | LN | Terminated | 1394 | ACR20 |
| NCT06105090 | Phase 2 | AS | Terminated | 1777 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R |